Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Company Deals

Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial

Fineline Cube May 19, 2026
Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Fineline Cube May 19, 2026
Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Fineline Cube May 19, 2026
Company Drug

Everest Medicines’ Nefecon NDA for IgAN Accepted for Review in Macao

Fineline Cube Aug 25, 2023

China-based Everest Medicines (HKG: 1952) has announced that its New Drug Application (NDA) for Nefecon,...

Policy / Regulatory

China Releases Third List of Pediatric Drugs to Guide Development and Filings

Fineline Cube Aug 25, 2023

The National Health Commission (NHC), National Healthcare Security Administration, National Medical Products Administration (NMPA), and...

Policy / Regulatory

NMPA Releases 72nd Batch of Reference Drugs for GQCE

Fineline Cube Aug 25, 2023

The National Medical Products Administration (NMPA) has released the 72nd batch of reference drugs for...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Receives European Commission Approval for Maternal Immunization

Fineline Cube Aug 25, 2023

Pfizer (NYSE: PFE) has received registration approval from the European Commission (EC) for its respiratory...

Company Drug

FDA Approves Gilead’s Veklury for COVID-19 Treatment in Patients with Hepatic Impairment

Fineline Cube Aug 25, 2023

The US Food and Drug Administration (FDA) has approved a new indication for Gilead’s (NASDAQ:...

Company Drug

AstraZeneca and MSD’s Lynparza Gets Green Light for Prostate Cancer Treatment in Japan

Fineline Cube Aug 25, 2023

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted AstraZeneca (AZ; NASDAQ: AZN) and...

Company

AstraZeneca Restructures to Capture Opportunities in Guangdong-Hong Kong-Macao Greater Bay Area

Fineline Cube Aug 25, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) is taking strategic steps to capitalize on the...

Company Deals

Cordavis Launches First Biosimilar: Novartis’ Hyrimoz to Compete with Humira

Fineline Cube Aug 25, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz’s biosimilar product, Hyrimoz (adalimumab), which references AbbVie’s...

Company Medical Device

Microport EP Medtech’s Cryoablation Catheter and Equipment Approved as Innovative Devices in China

Fineline Cube Aug 25, 2023

Shanghai Microport EP Medtech Co., Ltd has announced that its balloon type cryoablation catheter and...

Company Drug

CSPC Pharmaceutical’s Generic Entresto Approved in China for Heart Failure Treatment

Fineline Cube Aug 25, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Swiss...

Company Drug

Akeso Biopharma’s Ivonescimab Heads for Priority Review for NSCLC Treatment

Fineline Cube Aug 25, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that its bispecific antibody (BsAb) ivonescimab (AK112), targeting...

Company

3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing

Fineline Cube Aug 25, 2023

China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of...

Company Drug

GSK’s Shingrix Proves 100% Efficacy in Phase IV Trial for Chinese Patients

Fineline Cube Aug 24, 2023

UK-based pharmaceutical giant GSK plc (NYSE: GSK) has released efficacy data for its shingles vaccine,...

Company Deals

ImmuneOnco Biopharmaceuticals Launches IPO to Raise HKD 319 Million on Hong Kong Stock Exchange

Fineline Cube Aug 24, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) is poised to raise HKD 319 million (USD...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Approved by China’s NMPA for NSCLC Treatment

Fineline Cube Aug 24, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that it has received market approval...

Company Drug

Hinova Pharmaceuticals’ HP518 for mCRPC Accepted for Review by China’s NMPA

Fineline Cube Aug 24, 2023

Chengdu-based biotech company Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that the National Medical Products...

Company Deals

Labway Clinical Laboratory Partners with 10x Genomics for Precision Medicine Advancements

Fineline Cube Aug 24, 2023

Shanghai Labway Clinical Laboratory Co., Ltd., a leading provider of medical laboratory and pathological diagnostic...

Company Drug

Akeso Biopharma’s Ebdarokimab (AK101) NDA Accepted for Review by China’s CDE

Fineline Cube Aug 24, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that the New Drug Application (NDA) for its...

Policy / Regulatory

Beijing Drafts Regulations for Internet Diagnosis and Treatment, Prohibits AI Prescriptions

Fineline Cube Aug 24, 2023

The Beijing Municipal Health Commission has released the “Implementation Measures for Internet Diagnosis and Treatment...

Company

Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials

Fineline Cube Aug 24, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half...

Posts pagination

1 … 485 486 487 … 667

Recent updates

  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
  • BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader
  • China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases
  • Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial
  • Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.